01Mar 2025
iGlarLixi Achieves Faster, Better Glycaemic Control Than Gla-100 in T2D

iGlarLixi Achieves Faster, Better Glycaemic Control Than Gla-100 in T2D

iGlarLixi provides earlier, superior glycaemic control than Gla-100. In Asian patients with suboptimally controlled T2D, iGlarLixi reduced HbA1c more than Gla-100 (LixiLan-O-AP: −1.6% vs. −1.1%; LixiLan-L-CN: −1.3% vs. −0.5%). PPG reductions were greater, while FPG reductions and hypoglycaemia rates were similar. Median time to HbA1c and PPG targets was significantly shorter. These findings highlight iGlarLixi’s advantage for early glycaemic control.

  • #endo-diabetology

Like

Save

Share